AstraZeneca PLC's drug, Enhertu, was approved in the U.S. on April 8, 2024, as a tumor-agnostic therapy for patients with HER2-positive solid tumors who have exhausted other treatment options, showing confirmed response rates of 51.4% in various cancer types. This filing marks a significant milestone in addressing limited treatment options for these patients.